SecBot SecBot
SECBOTREPLAY Home › Report › KROS

KROS · Keros Therapeutics updated its corporate presentation for investor…

Keros Therapeutics, Inc. · 8-K filed Mar 4, 2026 at 16:09 ET

At the news

MIXEDIMPACT 5/10

8-K filed Mar 4, 2026 at 16:09 ET

Keros Therapeutics updated its corporate presentation for investor meetings, disclosing clinical trial timelines and preclinical data for its drug candidates rinvatercept and elritercept. The company expects to initiate a Phase 2 trial for Duchenne Muscular Dystrophy in Q2 2026 and engage regulators on an ALS trial in H2 2026. The presentation also highlights the $1.3 billion global licensing deal with Takeda for elritercept.

  • Updated corporate presentation includes clinical development timelines for rinvatercept (DMD and ALS) and elritercept (MDS)
  • Phase 2 DMD trial expected to commence in Q2 2026
  • Regulatory engagement for ALS trial planned in H2 2026
  • Takeda licensing agreement for elritercept includes $200M upfront payment and over $1.1B in potential milestones

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access